{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:50:07Z","timestamp":1769640607958,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clinthera.2011.12.017","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T10:54:29Z","timestamp":1327056869000},"page":"259-271","source":"Crossref","is-referenced-by-count":17,"title":["Velaglucerase Alfa for the Management of Type 1 Gaucher Disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Jennifer L.","family":"Morris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.12.017_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00128072-200204070-00001","article-title":"Gaucher disease: pediatric concerns","volume":"4","author":"Elstein","year":"2002","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.clinthera.2011.12.017_bib2","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month extension","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.12.017_bib3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00018-005-5437-0","article-title":"Therapeutic strategies to ameliorate lysosomal storage disorders\u2014a focus on Gaucher disease","volume":"63","author":"Swarker","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clinthera.2011.12.017_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2010.07.008","article-title":"Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease","volume":"46","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2011.12.017_bib5","series-title":"VPRIV (velaglucerase alfa) [prescribing information]","year":"2010"},{"key":"10.1016\/j.clinthera.2011.12.017_bib6","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1053\/j.gastro.2010.04.021","article-title":"The US Food and Drug Administration approves a new Gaucher disease drug","volume":"138","author":"Lang","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2011.12.017_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2011.12.017_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2011.04.005","article-title":"Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction","volume":"47","author":"Elstein","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2011.12.017_bib9","series-title":"ClinicalTrials.gov [Internet]","article-title":"Study of GA-GCB enzyme replacement therapy in type 1 Gaucher disease in patients previously treated with imiglucerase","year":"2000"},{"key":"10.1016\/j.clinthera.2011.12.017_bib10","series-title":"ClinicalTrials.gov [Internet]","article-title":"A study of Gene-Activated\u00ae Human Glucocerebrosidase (GA-GCB) enzyme replacement therapy in Gaucher Disease","year":"2000"},{"key":"10.1016\/j.clinthera.2011.12.017_bib11","first-page":"S8","article-title":"Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease","volume":"99","author":"Zimran","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2011.12.017_bib12","series-title":"ClinicalTrials.gov [Internet]","article-title":"A study of gene-activated\u00ae human glucocerebrosidase (GA-GCB) ERT compared with Imiglucerase in type 1 Gaucher disease","year":"2000"},{"key":"10.1016\/j.clinthera.2011.12.017_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2011.12.017_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcmd.2011.09.009","article-title":"Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem","volume":"48","author":"Elstein","year":"2012","journal-title":"Blood Cells Mol Dis"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2011.12.017_bib15","first-page":"75","article-title":"Antigenic differences in patients with type 1 Gaucher disease receiving velaglucerase alfa or imiglucerase enzyme replacement therapy in controlled clinical trials","volume":"95","author":"Ruiz","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2011.12.017_bib16","doi-asserted-by":"crossref","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","article-title":"Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811008873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811008873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:26:28Z","timestamp":1543278388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811008873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0149291811008873"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.12.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}